Showing 131-140 of 179 results for "".
Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.New Drugs in Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-drugs-in-psoriasis/20933/The last two years have seen a number of new drugs approved to treat psoriasis—from targeted biologics to new topicals.How to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.Lupus erythematosus tumidus vs Jessner's lymphocytic infiltrate of the Skin
https://practicaldermatology.com/topics/general-topics/lupus-erythematosus-tumidus-vs-jessners-lymphocytic-infiltrate-of-the-skin/21686/A systematic comparison of clinical and histologic characteristics.Are We All Clear?
https://practicaldermatology.com/topics/psoriasis/are-we-all-clear/20725/Understanding the safety of biologics for psoriasis in real-world settings.When to Consider Therapeutic Switching in Plaque Psoriasis: Best Practices for Nurse Practitioners, Physician Assistants, and Physicians
https://practicaldermatology.com/topics/psoriasis/when-to-consider-therapeutic-switching-in-plaque-psoriasis-best-practices-for-nurse-practitioners-physician-assistants-and-physicians/21054/What to know about patient experiences and the proper approaches to modifying treatment regimens.New Oral Agent May Shift Psoriasis Treatment Landscape
https://practicaldermatology.com/topics/psoriasis/new-oral-agent-may-shift-psoriasis-treatment-landscape/21258/A notable approval in 2014, apremilast may play an important role in bridging a wide gap in the care of moderate to severe psoriasis.Revisiting Cyclosporine in the Age of Biologics: Update on Efficacy and Mechanism of Action
https://practicaldermatology.com/topics/general-topics/revisiting-cyclosporine-in-the-age-of-biologics-update-on-efficacy-and-mechanism-of-action/21937/Increased understanding of the immunologic basis of psoriasis supports the role of cyclosporine in patient management.Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethNext-Generation TYK2 Inhibitors in Psoriasis
https://practicaldermatology.com/topics/psoriasis/next-generation-tyk2-inhibitors-in-psoriasis/60985/Phase 3 clinical data and emerging therapeutic implications demonstrate the promise of zasocitinib and envudeucitinib.